7:16 AM ET
8-K
Leadership Change
Q32 Bio Leadership Change
Q32 Bio appointed José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. Both executives bring extensive experience in late-stage clinical development and regulatory strategy as the company prepares to advance bempikibart into a registration-directed program for alopecia areata in 2027.